- Home
- RCEL vs ENTX Comparison
RCEL vs ENTX Comparison
Compare RCEL & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- ENTX
- Stock Information
- Founded
- RCEL N/A
- ENTX 2010
- Country
- RCEL United States
- ENTX Israel
- Employees
- RCEL N/A
- ENTX N/A
- Industry
- RCEL Medical/Dental Instruments
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RCEL Health Care
- ENTX Health Care
- Exchange
- RCEL Nasdaq
- ENTX Nasdaq
- Market Cap
- RCEL 113.7M
- ENTX 91.3M
- IPO Year
- RCEL N/A
- ENTX 2018
- Fundamental
- Price
- RCEL $4.56
- ENTX $1.80
- Analyst Decision
- RCEL Strong Buy
- ENTX Strong Buy
- Analyst Count
- RCEL 4
- ENTX 1
- Target Price
- RCEL $13.75
- ENTX $10.00
- AVG Volume (30 Days)
- RCEL 282.4K
- ENTX 73.4K
- Earning Date
- RCEL 11-06-2025
- ENTX 11-07-2025
- Dividend Yield
- RCEL N/A
- ENTX N/A
- EPS Growth
- RCEL N/A
- ENTX N/A
- EPS
- RCEL N/A
- ENTX N/A
- Revenue
- RCEL $74,884,000.00
- ENTX $166,000.00
- Revenue This Year
- RCEL $28.23
- ENTX N/A
- Revenue Next Year
- RCEL $35.24
- ENTX N/A
- P/E Ratio
- RCEL N/A
- ENTX N/A
- Revenue Growth
- RCEL 38.32
- ENTX 191.23
- 52 Week Low
- RCEL $3.60
- ENTX $1.50
- 52 Week High
- RCEL $14.16
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- RCEL 46.58
- ENTX 39.27
- Support Level
- RCEL $4.12
- ENTX $1.83
- Resistance Level
- RCEL $4.44
- ENTX $2.22
- Average True Range (ATR)
- RCEL 0.25
- ENTX 0.11
- MACD
- RCEL 0.03
- ENTX -0.02
- Stochastic Oscillator
- RCEL 50.00
- ENTX 0.00
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.